ADMA BIOLOGICS INC (ADMA) Stock News
NASDAQ:ADMA - Nasdaq - US0008991046 - Common Stock - Currency: USD
ADMA Latest News, Press Releases and Analysis
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business."
There May Still Be Time to Get in on These 3 Trending Biotechs
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86.
ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
SpringWorks Therapeutics Stock Gets A RS Rating Lift
The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.
ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025
ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end...
Arcellx Stock Earns 82 Relative Strength Rating
Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.
ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
Cash on Hand Utilized to Repay $30 Million of Senior Secured Term Loan Facility to Ares Capital Lowers ADMA’s Total Debt to $75 Million, a 29% Reduction ...
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors...
BioNTech Stock Got A IBD RS Rating Lift
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance.
Vericel Stock Sees RS Rating Shoot Higher
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.
Kirby McInerney LLP Reminds ADMA Biologics, Inc. (ADMA) Investors of Shareholder Investigation
ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against ADMA Biologics, Inc. (ADMA)
ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fraud Investigation with the Schall Law Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors...
ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle
The company signed on a new accounting firm less than a month after its previous accountant resigned unexpectedly.
ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET
ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET...
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors...